Background. A recent clinical trial could not find differences between anti-inflammatory drugs, antibiotics and placebo in shortening the duration of symptoms in acute bronchitis. Objectives. To investigate if C-reactive protein (CRP) concentrations at presentation are predictive of symptom resolution in these patients. Methods. We performed a secondary analysis of the data from a placebo-controlled, randomized clinical trial carried out in primary care. Patients from 18 to 70 years of age presenting a respiratory tract infection of <1 week of evolution, with cough as the predominant symptom and the presence of discoloured expectoration, were enrolled in the study. On the baseline visit, CRP was determined in capillary blood and a five-item symptom diary was given. Patients were followed up to 30 days. The main outcome measure was the number of days with persistent cough. Results. A total of 312 subjects fulfilled all the criteria for the efficacy analysis and had undergone the CRP test; of these, 56.4% presented a CRP value <8 mg/l and 76% presented <20 mg/l. There were no significant differences in the median duration of cough: 10 days among patients with CRP concentrations <8 mg/l [95% confidence interval (CI): 8-11 days], 11 days among those with concentrations ranging from 8 to 19 mg/l (95% CI: 8-16) and 11 days in those with CRP >20 mg/l (95% CI: 9-12) (P = 0.337). Conclusion. Among patients with uncomplicated acute bronchitis and discoloured sputum, the CRP concentrations at presentation are not helpful for predicting symptom resolution.
Introduction
Acute cough as the key feature of acute respiratory tract infections is one of the most common conditions managed in primary care (1) . Patients often return to their physician or seek other medical help because of the persistence of symptoms (2) . Practice guidelines do not recommend antibiotic treatment for acute bronchitis (3) , but between 52% and 100% (median: 88%) of patients are currently prescribed an antibiotic (1) . We recently carried out a clinical trial evaluating the efficacy of ibuprofen compared to amoxicillin-clavulanate and placebo in a group of adult patients with acute bronchitis and discoloured expectoration. In this study, we found weak evidence to reject the hypothesis of equal efficacy in shortening the duration of symptoms (4) . Point-of-care testing for C-reactive protein (CRP) was introduced into community clinical practice in the early 1990s, and it was rapidly adopted into routine clinical practice in some countries, especially in Northern Europe. In 2005, 42% of Swedish patients consulting a GP for a respiratory tract infection were tested for CRP (5) . This test provides results in ~3 minutes that help in guiding antibiotic treatment decisions. Several randomized clinical trials and observational studies have found that CRP rapid testing significantly reduces antibiotic prescribing for patients with lower respiratory tract infections (6) (7) (8) . Several guidelines recommend the use of this rapid test to distinguish uncomplicated acute bronchitis from severe respiratory tract infections, such as pneumonia (9, 10) . However, the utilization of the test for predicting clinical evolution of patients with uncomplicated acute cough is still controversial (11) (12) (13) . Therefore, in this study, we evaluated the predictive value of CRP concentrations at presentation with the clinical resolution of symptoms of acute bronchitis with discoloured sputum.
Methods
We used the data of patients recruited in a randomized clinical trial who had undergone a CRP rapid test (4) . Eligible participants were patients from 18 to 70 years of age presenting symptoms of a respiratory infection of <1 week of evolution with cough as the predominant symptom and with the presence of discoloured sputum and at least one other criterion of lower respiratory tract infection such as dyspnoea, wheezing, chest discomfort or chest pain. Patients were asked about the colour of their sputum which was designated as pale yellow or yellowish green as described by Stockley et al. (14) . Patients with radiological signs of pneumonia, signs of severe infection (confusion, respiratory rate > 25 breaths per minute or pulse > 120 beats per minute) and associated significant comorbidity, such as bronchial asthma, chronic bronchitis or chronic obstructive pulmonary disease (COPD), moderate-severe heart failure, dementia, stroke, immunosuppression or the use of immunosuppressive drugs were excluded.
On the inclusion visit, a CRP rapid test was performed in capillary blood using QuikRead CRP® analysers (Orion Diagnostica, Espoo, Finland). This analyser detects CRP levels between 8 and 160 mg/l and concentrations >160 mg/l and <8 mg/l are not given and are shown as >160 or <8, respectively. We categorized the CRP concentrations into three groups: those with the lowest levels, i.e. <8 mg/l (lower limit of detection), from 8 to 19 mg/l or ≥20 mg/l, since this is the threshold most frequently considered as an elevated level (15) (16) (17) .
A symptom diary and instructions as to how to fill it in was given to patients. This diary was previously validated (18) and consists of five items: disease severity, day-time cough, nighttime cough, limitation in daily activity and febrile sensation.
Each of the items was scored from 0 to 4, resulting in a range of scores from 0 to 20, with higher scores representing worse symptoms (18) .
Outcomes
Patients were followed up to 30 days after the baseline visit and three different outcomes were considered. The first outcome was the number of days with persistent cough, i.e. the number of days from the baseline visit until the patient last scored one or more in both the day-time cough and the night-time cough items in the symptom diary. The second outcome was the time to resolution of the total symptom scores until the patient last scored one in the five items; and the third was the clinical evolution assessed at day 11-13, since patients were randomized to anti-inflammatory drug, antibiotic or placebo for 10 days and it constituted the end-of-therapy visit. Clinical success was considered when disappearance or resolution of the symptoms was observed without the need for a new treatment.
Statistical analysis
A descriptive analysis of the baseline characteristics was performed using frequencies (percentages) and means (SD), and comparison between groups was performed using analysis of variance for continuous variables and Fisher test for categorical variables. Comparisons of clinical efficacy depending on exposure group were performed using Kruskal-Wallis tests to compare the median number of days until resolution of the different symptoms and the Fisher test to compare percentages of patients with clinical success at day 11-13. Survival analyses were carried out using Kaplan-Meier curves to analyse the time until cure of the different symptoms depending on the exposure group. Comparison between the different survival curves was undertaken using the log-rank test. Multivariate regression analysis was performed using the Cox Proportional Hazards model. We included potential confounders in progressive models: model 1 (crude model), model 2 (including the treatment administered-ibuprofen, amoxicillin and clavulanate or placebo-and the baseline characteristics that were significantly different between the groups) and model 3 (treatment group and baseline severity defined as the presence of two or more of temperature >38°C, age ≥55 years, current smoker, dyspnoea, wheezing and/or yellowish green sputum). The proportionality of the hazards assumption was evaluated using Schoenfeld residuals and comparing the estimated log-minus-log survivor curves over the different categories of variables investigated. All results are expressed with 95% confidence intervals (CIs). The level of significance was considered at 5%, and all the analysis were performed using STATA/SE 12.1 (Stata Corporation, College Station, TX).
Results

Patient characteristics
A total of 433 subjects were invited to participate in the study. Seventeen did not fulfil any of the inclusion criteria or had at least one of the exclusion criteria. A chest X-ray was performed in seven cases, one of which was positive for pneumonia. CRP rapid testing was not available in three of the nine primary health care centres. Of the patients who finally participated in this study, the CRP rapid test procedure was not performed in 104 cases, leaving 312 valid for analysis. Age was slightly higher among patients who underwent CRP rapid testing compared to those who did not undergo the test (45.2 versus 44.5 years) and there were fewer men in the former (43.6 versus 47.1, respectively), without significant statistical differences being observed. None of the baseline characteristics was statistically significantly different between subjects with and without CRP rapid test procedures (results not shown). Of the total number of 312 subjects, 13 patients did not provide complete information about the symptom diary and it was not possible to evaluate two of the outcomes. The flow of patients in the study is presented in Fig. 1 .
The mean (SD) age was 45.2 (14.5) years and 136 were male (43.6%). A total of 176 (56.4%) patients with CRP determination presented values <8 mg/l, 61 (19.6%) presented a concentration between 8 and 19 and 75 (24%) patients had a value of 20 mg/l or greater. The demographic and clinical characteristics of the population were well matched between the groups with different CRP concentrations, except for the colour of sputum and body temperature, with greater CRP concentrations associated with greenish expectoration and with a higher number of patients with a high temperature ( Table 1) .
Association between CRP values and clinical resolution
No statistically significant association was observed between the CRP concentrations and the duration of cough, although patients with CRP concentrations <8 mg/l presented a slightly shorter duration of cough (median of 10 days; 95% CI: 8-11 days) compared to patients with concentrations ranging from 8 and 19 mg/l (11 days; 95% CI: 8-16) and those with higher CRP concentrations (11 days; 95% CI: 9-12 days) (logrank test P = 0.337) (Fig. 2a) . Regarding the analysis of days with any symptom, the median duration of days until all the symptoms disappeared was not significantly different between the three categories of CRP concentrations (log-rank test P = 0.397) ( Table 2) (Fig. 2b) . Of the 176 patients with CRP concentrations <8 mg/l, 157 (89.2%) presented clinical success at day 11-13, being slightly higher, but not significantly, than among patients with intermediate levels (80.3%) and those with higher levels (84.0%) (P = 0.159) ( Table 2 ). The multivariate Cox Proportional Hazards models showed that patients with CRP levels >8 mg/l presented a slightly longer duration of symptoms. The crude hazard ratio (HR) was 0.84 (95% CI: 0.60-1.18) for the intermediate group and 0.83 (95% CI: 0.61-1.13) for the higher group. Results did not change substantially after adjustment for several covariates (Table 3) . Due to the similar estimates for the two groups, we performed a subanalysis combining the two categories for intermediate and higher CRP concentrations groups into one. CIs were narrowed but none of the estimates was statistically significantly different than 1 (results not shown). The interactions between exposure and different covariates were tested and none was significant or seemed to adjust the data better. Results for the Cox Proportional Hazards models showed a slightly longer duration of symptoms than those obtained only with cough symptoms (results not shown).
Discussion
Summary
This study has shown that CRP concentrations at presentation with acute bronchitis and discoloured sputum do not provide any prognostic information about the time to resolution of symptoms.
Strengths and weaknesses of the study
This study shows a subanalysis of data collected in a randomized clinical trial. The fact that some of the subjects did not have a CRP rapid test could lead to a selection bias but the baseline characteristics were not different among the subjects with and without the test. This is likely to be because the test was performed depending on the centre in which the patients were attended and had nothing to do with their characteristics. This loss of subjects could lead to an insufficient powered analysis to detect differences between groups. This could have happened if there had been a systematic difference between the survival curves but too small to be considered statistically significant. However, this was not the case because we observed that the survival curves randomly overlapped each other over time.
The CRP levels can vary considerably depending on the day this biomarker is measured in the course of the infection. Maximum CRP values are reached at days 2-4 and fall rapidly over the following days (19) . However, only patients with cough lasting <7 days were included in this study, thereby minimizing the variability in the CRP result. Higher CRP concentrations were found significantly more frequently in patients with fever than in those without. However, resolution of the different symptoms was similar regardless of whether they had been treated or not with antibiotics, making this bias very unlikely to have occurred. In addition, no statistically significant differences were observed in the adjusted models either.
Comparison with existing literature
In our study, approximately three quarters of the patients with acute bronchitis had CRP levels <20 mg/l, similar to what has been observed previously. In a sample of 227 patients with acute bronchitis, Cals et al. reported that 69% of the patients had test results <20 mg/l (8). In another study, 67% of the patients with lower respiratory tract infections had CRP concentrations of 10 mg/l or less (12) . In contrast, Hopstaken et al. observed a median level of 22.5 mg/l (11); however, they included more severe patients and 13% were diagnosed with COPD and another 13.2% with pneumonia. The CRP test is regarded as helpful in patients with lower respiratory tract infections when the diagnosis is not straightforward, since very high values (>100 mg/l) indicate a severe infection or inflammatory response due to other severe diseases, and some studies have shown that the CRP test better predicts pneumonia than the use of only clinical findings (20) . Other studies observed that CRP levels were significantly increased in purulent versus mucoid exacerbations in patients with COPD (21). However, this may not apply to otherwise healthy individuals with acute cough. Discoloured sputum is commonly interpreted by both patients and physicians as a clinical sign of the presence of bacterial infection even in patients without COPD. In a study with patients with acute bronchitis, the positive likelihood ratio for bacterial infection was 1.46 in patients with yellowish or greenish sputum compared to those with acute cough and colourless sputum (22) . Patients with colourless sputum were not included in our study, but we distinguished patients with pale yellow from those with a yellowish green colour, being the CRP value significantly higher among the latter. The resolution of symptoms was, however, similar in both groups. Despite that, yellowish and greenish sputum have been demonstrated to be strong predictors for antibiotic prescribing in patients with acute bronchitis in primary care. Butler et al. showed that GPs are 3-fold times more prone to prescribe antibiotics in episodes of acute bronchitis with purulent sputum (23) . Guidelines do not recommend the utilization of antibiotic therapy in acute bronchitis even in patients with purulent sputum, since most systematic reviews have found no benefit from its use with the exception of a modest reduction in the duration of symptoms, not confirmed in our study (3) . In a recent placebocontrolled clinical trial including >2000 adult patients with acute cough of <1 month duration as the prominent symptom and once pneumonia was excluded on the basis of clinical grounds, symptoms rated moderately bad or worse lasted a median of 6 days among patients treated with amoxicillin versus 7 days observed with placebo, with a difference not being significant (HR: 1.06) (24) . A recent meta-analysis, with the inclusion of 17 trials with nearly 4000 subjects, clearly indicates that antibiotics are not more effective than placebo among patients with acute bronchitis (3). Engel et al. demonstrated the limited use of CRP rapid testing in a systematic review published in 2012 (15) . However, this evidence has not been translated into a more rational of both rapid testing and antibiotic prescribing. Despite being ineffective, current percentages of antibiotic prescribing in acute bronchitis have increased in the last years in Western countries (25) . The present study, with the inclusion of patients with only purulent expectoration, also fails to demonstrate any benefit of CRP testing.
The impact of CRP point-of-care testing on patient outcomes has been assessed in two randomized clinical trials including 688 primary care patients with respiratory tract infection, showing that antibiotic prescribing in patients managed with CRP rapid testing was lower than in the control group without adversely affecting patient satisfaction or recovery (8, 26) . Several studies have shown that antibiotic prescribing increases with increasing CRP levels in patients with acute bronchitis (11) (12) (13) , although patients with higher levels were not associated with a worse prognosis, as we have confirmed in our study. The study populations of the previous three studies, however, differed greatly. In a systematic review with the inclusion of these studies, Engel et al. did not find CRP to be a good marker for prognosis in patients with acute bronchitis in primary care (15) . In a Norwegian study, patients with a CRP level of ≥11 mg/l presented a slightly shorter duration of illness with a relative risk of 1.16 (95% CI: 1.1-1.3) when compared to patients with normal CRP values measured at index consultation, but this difference was not statistically significant. Slow recovery was also associated with age >60 and absence of fever (12) . The authors did not rule out the presence of patients with COPD in this study, which could explain why older patients also had a slower recovery.
In conclusion, we did not find evidence to recommend CRP rapid testing in the consultation in patients with acute bronchitis and without chronic pulmonary disease even with the presence of purulent sputum, when pneumonia can be reasonably discarded on clinical grounds, since the result of the test has no influence on the prediction of symptom resolution or the choice of treatment. Overutilization of diagnostic tests can medicalize a problem that is self-limited. These results should be taken into account, especially in countries where CRP is routinely used, since its use in patients with otherwise uncomplicated acute bronchitis, even with purulent sputum, is not beneficial.
